Genomic biomarkers for patient selection and stratification: the cancer paradigm.

Moschos, Sterghios (2012) Genomic biomarkers for patient selection and stratification: the cancer paradigm. Bioanalysis, 4 (20). pp. 2499-511. ISSN 1757-6180

Full text not available from this repository.

Abstract

The revolution in disease diagnosis and treatment promised on the completion of the human genome project over a decade ago has materialized in the form of unified drug and biomarker discovery and development pipelines. This strategic shift has been principally catalyzed through success stories in the field of oncology, ushering in the era of personalized medicine. Thus, a number of molecular targets have also been demonstrated to be reliable markers for selecting patients wherein treatment can be efficacious. Perhaps more importantly, however, the late adoption of biomarker strategies has also rescued drug candidates from complete late-stage failure. This review examines the historical lessons of key challenges in translating biomarker assay information into strategic and clinically actionable decisions and assesses the impact of personalized genome sequencing in the future of companion diagnostic development and commercialization.

Item Type:	Article
Subjects:	C700 Molecular Biology, Biophysics and Biochemistry
Department:	Faculties > Health and Life Sciences > Applied Sciences
Depositing User:	Sterghios Moschos
Date Deposited:	24 Oct 2016 12:50
Last Modified:	12 Oct 2019 18:27
URI:	http://nrl.northumbria.ac.uk/id/eprint/28133

Downloads